Predicting new molecular targets for known drugs
暂无分享,去创建一个
Michael J. Keiser | J. Irwin | B. Shoichet | V. Setola | B. Roth | C. Laggner | A. Abbas | S. Hufeisen | Niels H. Jensen | M. Kuijer | Roberto C. Matos | Thuy B. Tran | R. Whaley | R. Glennon | J. Hert | Kelan Thomas | D. D. Edwards | T. Tran | Atheir I. Abbas | M. B. Kuijer | Kelan L Thomas | Christian Laggner
[1] The Theory and Practice of Chemotherapy , 1916, Proceedings of the Royal Society of Medicine.
[2] 北村 聖. "The New England Journal of Medicine". , 1962, British medical journal.
[3] A. Kurland,et al. Clinical trial of haloanisone (R-2028) with hospitalized psychiatric patients. , 1962, The Journal of new drugs.
[4] Robert S. Pinals,et al. A double‐blind, placebo‐controlled trial , 1986 .
[5] R. Mehvar,et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. , 1987, Drug metabolism and disposition: the biological fate of chemicals.
[6] Takeyama Shigeyuki,et al. Beta1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase , 1987 .
[7] T. Nagao,et al. Beta 1-adrenergic selectivity of the new cardiotonic agent denopamine in its stimulating effects on adenylate cyclase. , 1987, Biochemical pharmacology.
[8] M. Caron,et al. Molecular cloning and expression of the cDNA for the hamster alpha 1-adrenergic receptor. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[9] E. Myers,et al. Basic local alignment search tool. , 1990, Journal of molecular biology.
[10] M. Caron,et al. Molecular cloning and expression of the cDNA for the alpha 1A-adrenergic receptor. The gene for which is located on human chromosome 5. , 1991, The Journal of biological chemistry.
[11] [The effect of antihistaminic preparations on the binding of labelled mepyramine, ketanserin and quinuclidinyl benzilate in the rat brain]. , 1993, Eksperimental'naia i klinicheskaia farmakologiia.
[12] D. Sibley,et al. Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.
[13] E. sanders-Bush,et al. Agonist Properties of N,N-Dimethyltryptamine at Serotonin 5-HT2A and 5-HT2C Receptors , 1998, Pharmacology Biochemistry and Behavior.
[14] A. Zwinderman,et al. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. , 1998, Journal of clinical psychopharmacology.
[15] B. Roth,et al. The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .
[16] J. Amsterdam,et al. Interruption of selective serotonin reuptake inhibitor treatment , 2000, British Journal of Psychiatry.
[17] Delavirdine: a review of its use in HIV infection. , 2000, Drugs.
[18] Bryan L. Roth,et al. Salvinorin A: A potent naturally occurring nonnitrogenous κ opioid selective agonist , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[19] Ruedi Stoop,et al. An Ontology for Pharmaceutical Ligands and Its Application for in Silico Screening and Library Design , 2002, J. Chem. Inf. Comput. Sci..
[20] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[21] Dragos Horvath,et al. Predicting ADME properties and side effects: the BioPrint approach. , 2003, Current opinion in drug discovery & development.
[22] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[23] Effect of some antihistamine preparations on binding of3H-mepyramine and3H-cimetidine to histamine receptors in rat brain , 1992, Pharmaceutical Chemistry Journal.
[24] S. Peroutka,et al. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex , 2004, Psychopharmacology.
[25] Tudor I. Oprea,et al. Chemoinformatics in drug discovery , 2005 .
[26] Brian K. Shoichet,et al. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening , 2005, J. Chem. Inf. Model..
[27] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[28] B. Roth. Drugs and valvular heart disease. , 2007, The New England journal of medicine.
[29] D. Marona-Lewicka,et al. Further evidence that the delayed temporal dopaminergic effects of LSD are mediated by a mechanism different than the first temporal phase of action , 2007, Pharmacology Biochemistry and Behavior.
[30] Gerhard Dürnberger,et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. , 2007, Blood.
[31] Michal Vieth,et al. Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.
[32] A. Hopkins. Network pharmacology , 2007, Nature Biotechnology.
[33] Steffen Hering,et al. State-dependent dissociation of HERG channel inhibitors , 2007, British journal of pharmacology.
[34] Stuart L. Schreiber,et al. Chemical biology : from small molecules to systems biology and drug design , 2007 .
[35] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[36] Andreas Bender,et al. Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics , 2008, J. Chem. Inf. Model..
[37] Tudor I. Oprea,et al. WOMBAT and WOMBAT‐PK: Bioactivity Databases for Lead and Drug Discovery , 2008 .
[38] David J Newman,et al. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? , 2008, Journal of medicinal chemistry.
[39] Stuart L. Schreiber,et al. Large-scale chemical dissection of mitochondrial function , 2008, Nature Biotechnology.
[40] J. Bajorath. Computational analysis of ligand relationships within target families. , 2008, Current opinion in chemical biology.
[41] John A. Tallarico,et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.
[42] R. Leurs,et al. Human inflammatory dendritic epidermal cells express a functional histamine H4 receptor. , 2008, The Journal of investigative dermatology.
[43] Tudor I. Oprea,et al. Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..
[44] Randall T Peterson,et al. Chemical biology and the limits of reductionism. , 2008, Nature chemical biology.
[45] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[46] Bryan L Roth,et al. N-Desalkylquetiapine, a Potent Norepinephrine Reuptake Inhibitor and Partial 5-HT1A Agonist, as a Putative Mediator of Quetiapine's Antidepressant Activity , 2008, Neuropsychopharmacology.
[47] S. Grant,et al. PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors , 2009, The Journal of Neuroscience.
[48] M. Jackson,et al. The Hallucinogen N,N-Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator , 2009, Science.
[49] J. Peters,et al. Pharmacological Promiscuity: Dependence on Compound Properties and Target Specificity in a Set of Recent Roche Compounds , 2009, ChemMedChem.
[50] Alla Karnovsky,et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore , 2009, Proceedings of the National Academy of Sciences.
[51] David E Nichols,et al. WAY 100635 produces discriminative stimulus effects in rats mediated by dopamine D4 receptor activation , 2009, Behavioural pharmacology.
[52] Teruo Hayashi,et al. When the Endogenous Hallucinogenic Trace Amine N,N-Dimethyltryptamine Meets the Sigma-1 Receptor , 2009, Science Signaling.
[53] M. Fischbach,et al. Repurposing libraries of eukaryotic protein kinase inhibitors for antibiotic discovery , 2009, Proceedings of the National Academy of Sciences.
[54] Angelo D. Favia,et al. Protein promiscuity and its implications for biotechnology , 2009, Nature Biotechnology.
[55] B. Roth,et al. The expanded biology of serotonin. , 2009, Annual review of medicine.
[56] J. Heykants,et al. On the pharmacokinetics of domperidone in animals and man IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration , 2010, European Journal of Drug Metabolism and Pharmacokinetics.